Coherus Oncology, Inc.

Contributing Author

Recent Articles by Coherus Oncology, Inc.

9 hours	Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference CHRS -5.56% GlobeNewswire
Jan-05	Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114) CHRS GlobeNewswire
Dec-08	Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma CHRS GlobeNewswire
Nov-07	Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody CHRS GlobeNewswire
Nov-06	Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update CHRS GlobeNewswire
Nov-06	Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer CHRS GlobeNewswire
Oct-30	Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 CHRS GlobeNewswire
Oct-23	Coherus Oncology to Participate in Upcoming Investor Conferences CHRS GlobeNewswire
Oct-03	Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) CHRS GlobeNewswire
Sep-03	Coherus Oncology to Participate in Upcoming Investor Conferences CHRS GlobeNewswire
Aug-07	Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update CHRS GlobeNewswire
Jul-31	Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 CHRS GlobeNewswire
May-30	Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics CHRS GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.